3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[(4-acetylaminophenoxy)methyl]propanoic acid | 321584-98-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-2-[(4-acetylaminophenoxy)methyl]propanoic acid
• 英文别名: 2-[(4-Acetamidophenoxy)methyl]-3-[4-(4-chlorophenyl)phenyl]sulfonylpropanoic acid
• CAS: 321584-98-9
• 化学式: C₂₄H₂₂ClNO₆S
• 分子量: 487.961
• InChiKey: IKTSFGDWHPUSDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• 3-ARYLSULFONYL-2-(SUBSTITUTED METHYL)PROPANOIC ACID DERIVATES AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1200398A1

  公开（公告）日：2002-05-02
• PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1254137A1

  公开（公告）日：2002-11-06
• US6765003B1
  申请人：——

  公开号：US6765003B1

  公开（公告）日：2004-07-20
• [EN] 3-ARYLSULFONYL-2-(SUBSTITUTED METHYL)PROPANOIC ACID DERIVATES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES D'ACIDE 3-ARYLSULFONYL-2-(A SUBSTITUTION METHYL)PROPANOIQUE UTILISES COMME INHIBITEURS DE LA METALLOPROTEINASE A MATRICE
  申请人：PHARMACIA & UPJOHN SPA

  公开号：WO2001005756A1

  公开（公告）日：2001-01-25

  Compounds which are 3-arylsulfonyl-2-methyl propanoic acid derivatives of formula (I): wherein X is HO-NH- or HO-, R1 is selected from phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, benzamido (i.e., -NH-CO-Ph) and benzamido substituted on the terminal phenyl ring by C1-C4 alkyl, fluoro, chloro, cyano or C1-4 alkoxy; R2 is selected from (a) -S-Ar or -S-CH2-Ar wherein Ar is an aromatic moiety; (b) -O-Ar wherein Ar is as defined above; (c) -S-Het or -S-CH2-Het wherein Het is a heterocyclic ring; and (d) 2,5-dioxo-1-imidazolidinyl or 2,4-dioxo-1-imidazolinyl; and the pharmaceutically acceptable salts thereof; have potent and selective inhibitory activity against matrix metalloproteinases (MMPs) and can thus be used in the treatment and prevention of diseases mediated by MMPs.
• [EN] PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRIDO[2,3-D]PYRIMIDINE-2,7-DIAMINE KINASE
  申请人：WARNER LAMBERT CO

  公开号：WO2001055147A1

  公开（公告）日：2001-08-02

  Disclosed are compounds of the formula (I) wherein: R?2, R7, R13, R14¿ and R¿15? are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted -(CH2)nR?12; R5¿ is halogen, cyano, nitro, -R?9, -NR9R10¿, or -OR9; R6 is halogen, cyano, nitro, -R?9, -NR9R10, -OR9, -Co¿2R?9, -COR9, -CONR9R10, -NR9COR10¿, (un)substituted lower alkenyl, or (un)substituted lower alkynyl; R8 is -CO¿2?R?13, -COR13, -CONR13R14, -CSNR13R14, -C(NR13)NR14R15, -SO¿3R13, -S02R13, -SO2NR?13R14, -PO¿3R?13R14, -POR13R14¿, -PO(NR13R14)2; R?9 and R10¿ are independently hydrogen or (un)substituted lower alkyl; R11 is a heteroaryl or a heterocyclic group; R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.